Wendy L Dixon has an estimated net worth of $10.6 Million. This is based on reported shares across multiple companies, which include INCYTE CORP, BRISTOL MYERS SQUIBB CO, Orexigen Therapeutics, Inc., DENTSPLY INTERNATIONAL INC /DE/, Voyager Therapeutics, Inc., bluebird bio, Inc., ARVINAS, INC., Alkermes plc., Black Diamond Therapeutics, Inc., Eleven Biotherapeutics, Inc., Furiex Pharmaceuticals, Inc., IOVANCE BIOTHERAPEUTICS, INC., ZEVRA THERAPEUTICS, INC., ALKERMES INC, and Ardea Biosciences, Inc./DE.
2008 was Wendy L Dixon's most active year for acquiring shares with 20 total transactions. Wendy L Dixon's most active month to acquire stocks was the month of May. 2021 was Wendy L Dixon's most active year for disposing of shares, totalling 21 transactions. Wendy L Dixon's most active month to dispose stocks was the month of October. 2021 saw Wendy L Dixon paying a total of $2,799,105.89 for 172,681 shares, this is the most they've acquired in one year. In 2019 Wendy L Dixon cashed out on 106,668 shares for a total of $4,475,773.82, their largest year based on trade value.